<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484520</url>
  </required_header>
  <id_info>
    <org_study_id>M16-183</org_study_id>
    <nct_id>NCT03484520</nct_id>
  </id_info>
  <brief_title>A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well
      as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and
      venetoclax for patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 12, 2018</start_date>
  <completion_date type="Anticipated">August 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax of Venetoclax</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RPTD) of co-administered Dinaciclib and Venetoclax</measure>
    <time_frame>Minimum first cycle of dosing (21 days)</time_frame>
    <description>Tthe RPTD of co-administered venetoclax and dinaciclib will be determined during the dose escalation phase of the study. RPTD will be determined using available safety and pharmacokinetics data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Venetoclax</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Maximum observed plasma concentration (Cmax) for Venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of Venetoclax</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 Post-dose of Venetoclax</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Dinaciclib</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Maximum plasma concentration (Cmax) of dinaciclib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of Dinaciclib</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Half-life (t1/2) of dinaciclib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt Post-dose of Dinaciclib</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to time t (AUCt) post-dose dinaciclib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of Dinaciclib</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) post-dose of dinaciclib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of Dinaciclib</measure>
    <time_frame>Approximately 29 days after first dose of study drug</time_frame>
    <description>Clearance (CL) of dinaciclib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>CR is defined as the proportion of participants with documented complete response (CR) based on International Working Group (IWG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite CR Rate (CR + CRi)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>Composite is defined as CR + CRi (CR with incomplete blood count recovery) based on IWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>ORR is defined as the proportion of participants with documented partial response (PR) or better (CR + CRi + partial response [PR]) based on IWG criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Venetoclax + Dinaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet, oral</description>
    <arm_group_label>Venetoclax + Dinaciclib</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinaciclib</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Venetoclax + Dinaciclib</arm_group_label>
    <other_name>MK-7965</other_name>
    <other_name>SCH-727965</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acute myeloid leukemia (AML) by World Health Organization criteria
             excluding acute promyelocytic leukemia (APL)-M3.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

          -  Participant must have adequate hematologic, renal, and liver function laboratory
             values as described in the protocol.

        Exclusion Criteria:

          -  Known central nervous system leukemia

          -  Severe chronic obstructive pulmonary disease (COPD) with hypoxemia

          -  History of any malignancy within the last 6 months except for those specified in this
             protocol and low-grade malignancies not requiring active treatment.

          -  Prior allogeneic stem cell transplant within 6 months of study drug administration and
             no requirement for graft versus host therapy.

          -  History of clinically significant medical condition that, in the opinion of the
             investigator, would adversely affect participation in this study.

          -  Known active infection with human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicin</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Univ de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer, Acute Myeloid Leukemia (AML), venetoclax, dinaciclib, Relapsed/refractory AML, Pharmacokinetics, Venetoclax, Dinaciclib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

